RGBP

Regen Biopharma, Inc. is a biotechnology company. The Company is focused on identifying regenerative medicine applications in the stem cell/immunotherapy space and advancing these technologies through pre-clinical and Phase I/II clinical trials. The Company is developing products treating blood disorders using small molecules and gene silencing, treating cancer with immunotherapy, modulating molecular processes in cancer stem cell through its molecular targeting approaches, and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients. The Company's products include HemaXellarate I, HemaXellerate II, dCellVax, NR2F6 and Tcellvax. The Company is also identifying small molecules through a screening program that inhibits NR2F6 leading to immune cell activation for oncology applications. The Company is also developing drugs that modulate telomere maintenance.